Axial

Share this post
Axial - Cipher #7 (bispecifics)
axial.substack.com

Axial - Cipher #7 (bispecifics)

Finding the other half

Joshua Elkington
Aug 8, 2019
Comment
Share

Analysis of public clinical and business development data in life sciences.

Bispecifics are protein therapeutics that engage T-cells with a target; recently showing tremendous amount of growth in the clinic and research:

Source: BioCentury

With Regeneron being the largest leader in the field:

Source: Regeneron

Where the average bispecific deal value increasing over time and a share increase in the number of partnerships in 2014/2015 when cell therapies were getting approved and bispecifics were seen as a viable/lower cost alternative:

With the deals focused on oncology:

And development and licensing agreements:

Focused on discovery and preclinical work:

With deals having no geographic preference:

Thank you.

CommentComment
ShareShare

Create your profile

0 subscriptions will be displayed on your profile (edit)

Skip for now

Only paid subscribers can comment on this post

Already a paid subscriber? Sign in

Check your email

For your security, we need to re-authenticate you.

Click the link we sent to , or click here to sign in.

TopNewCommunity

No posts

Ready for more?

© 2022 Axial
Privacy ∙ Terms ∙ Collection notice
Publish on Substack Get the app
Substack is the home for great writing